tactile systems technology inc - TCMD
TCMD
Close Chg Chg %
18.92 -0.59 -3.12%
Closed Market
18.33
-0.59 (3.12%)
Volume: 909.31K
Last Updated:
Nov 26, 2024, 4:00 PM EDT
Company Overview: tactile systems technology inc - TCMD
TCMD Key Data
| Open $21.02 | Day Range 18.33 - 21.09 |
| 52 Week Range 11.12 - 19.55 | Market Cap $454.03M |
| Shares Outstanding 24.00M | Public Float 23.27M |
| Beta 1.17 | Rev. Per Employee N/A |
| P/E Ratio 29.44 | EPS $0.65 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 339.94K |
TCMD Performance
| 1 Week | 5.99% | ||
| 1 Month | 33.24% | ||
| 3 Months | 38.20% | ||
| 1 Year | 35.24% | ||
| 5 Years | -70.53% |
TCMD Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
5
Full Ratings ➔
About tactile systems technology inc - TCMD
Tactile Systems Technology, Inc. engages in developing and providing medical devices for the treatment of underserved chronic diseases. It provides lymphedema solutions and offers Flexitouch Plus and Entre Plus systems products. The company was founded on January 30, 1995 and is headquartered in Minneapolis, MN.
TCMD At a Glance
Tactile Systems Technology, Inc.
3701 Wayzata Boulevard
Minneapolis, Minnesota 55416
| Phone | 1-612-355-5100 | Revenue | 274.42M | |
| Industry | Medical Specialties | Net Income | 28.52M | |
| Sector | Health Technology | 2023 Sales Growth | 11.199% | |
| Fiscal Year-end | 12 / 2024 | Employees | 992 | |
| View SEC Filings |
TCMD Valuation
| P/E Current | 27.778 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 11.622 |
| Price to Sales Ratio | 1.208 |
| Price to Book Ratio | 1.743 |
| Price to Cash Flow Ratio | 9.276 |
| Enterprise Value to EBITDA | 14.511 |
| Enterprise Value to Sales | 1.169 |
| Total Debt to Enterprise Value | 0.157 |
TCMD Efficiency
| Revenue/Employee | 276,636.089 |
| Income Per Employee | 28,744.96 |
| Receivables Turnover | 4.784 |
| Total Asset Turnover | 1.012 |
TCMD Liquidity
| Current Ratio | 3.539 |
| Quick Ratio | 2.99 |
| Cash Ratio | 1.487 |
TCMD Profitability
| Gross Margin | 70.177 |
| Operating Margin | 5.672 |
| Pretax Margin | 5.747 |
| Net Margin | 10.391 |
| Return on Assets | 10.511 |
| Return on Equity | 18.102 |
| Return on Total Capital | 11.686 |
| Return on Invested Capital | 13.374 |
TCMD Capital Structure
| Total Debt to Total Equity | 26.015 |
| Total Debt to Total Capital | 20.644 |
| Total Debt to Total Assets | 17.518 |
| Long-Term Debt to Equity | 23.038 |
| Long-Term Debt to Total Capital | 18.282 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Tactile Systems Technology Inc - TCMD
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 187.13M | 208.06M | 246.78M | 274.42M | |
Sales Growth
| -1.25% | +11.18% | +18.61% | +11.20% | |
Cost of Goods Sold (COGS) incl D&A
| 54.32M | 59.11M | 74.58M | 81.84M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 2.79M | 3.68M | 6.27M | 6.54M | |
Depreciation
| 2.39M | 2.28M | 2.50M | 2.70M | |
Amortization of Intangibles
| 400.00K | 1.40M | 3.77M | 3.84M | |
COGS Growth
| -1.69% | +8.81% | +26.17% | +9.74% | |
Gross Income
| 132.81M | 148.95M | 172.21M | 192.58M | |
Gross Income Growth
| -1.06% | +12.15% | +15.61% | +11.83% | |
Gross Profit Margin
| +70.97% | +71.59% | +69.78% | +70.18% |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 132.84M | 149.24M | 174.30M | 177.02M | |
Research & Development
| 5.26M | 5.66M | 7.09M | 7.82M | |
Other SG&A
| 127.57M | 143.58M | 167.21M | 169.19M | |
SGA Growth
| +8.32% | +12.34% | +16.80% | +1.56% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | 2.40M | 10.66M | (2.48M) | |
EBIT after Unusual Expense
| (2.43M) | (285.16K) | (12.76M) | 18.04M | |
Non Operating Income/Expense
| 167.00K | (531.00K) | (2.71M) | (2.27M) | |
Non-Operating Interest Income
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (2.26M) | (2.29M) | (15.47M) | 15.77M | |
Pretax Income Growth
| -120.32% | -1.42% | -574.79% | +201.92% | |
Pretax Margin
| -1.21% | -1.10% | -6.27% | +5.75% | |
Income Tax
| (1.64M) | 9.52M | 2.39M | (12.74M) | |
Income Tax - Current - Domestic
| (413.00K) | (712.00K) | 2.42M | 6.63M | |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| (1.23M) | 10.23M | (32.00K) | (19.38M) | |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (620.00K) | (11.81M) | (17.87M) | 28.52M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (620.00K) | (11.81M) | (17.87M) | 28.52M | |
Net Income Growth
| -105.65% | -1,805.00% | -51.27% | +259.60% | |
Net Margin Growth
| -0.33% | -5.68% | -7.24% | +10.39% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (620.00K) | (11.81M) | (17.87M) | 28.52M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (620.00K) | (11.81M) | (17.87M) | 28.52M | |
EPS (Basic)
| -0.032 | -0.599 | -0.8903 | 1.2438 | |
EPS (Basic) Growth
| -105.52% | -1,771.87% | -48.63% | +239.71% | |
Basic Shares Outstanding
| 19.35M | 19.72M | 20.07M | 22.93M | |
EPS (Diluted)
| -0.032 | -0.599 | -0.8903 | 1.2304 | |
EPS (Diluted) Growth
| -105.73% | -1,771.87% | -48.63% | +238.20% | |
Diluted Shares Outstanding
| 19.35M | 19.72M | 20.07M | 23.18M | |
EBITDA
| 2.77M | 3.40M | 4.17M | 22.11M | |
EBITDA Growth
| -81.73% | +22.77% | +22.92% | +429.59% | |
EBITDA Margin
| +1.48% | +1.63% | +1.69% | +8.06% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 21.00 | |
| Number of Ratings | 5 | Current Quarters Estimate | 0.315 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | 0.615 | |
| Last Quarter’s Earnings | 0.21 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 1.273 | Next Fiscal Year Estimate | 0.848 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 4 | 4 | 4 | 4 |
| Mean Estimate | 0.32 | -0.05 | 0.62 | 0.85 |
| High Estimates | 0.35 | 0.04 | 0.65 | 0.92 |
| Low Estimate | 0.25 | -0.13 | 0.55 | 0.80 |
| Coefficient of Variance | 14.08 | -145.14 | 7.21 | 6.49 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 3 | 5 | 4 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 2 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Buy | Buy |
SEC Filings for Tactile Systems Technology Inc - TCMD
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Tactile Systems Technology Inc - TCMD
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| May 21, 2024 | Elaine M. Birkemeyer Chief Financial Officer | 61,295 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $13.68 per share | 838,515.60 |
| May 13, 2024 | William W. Burke Director | 35,742 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 13, 2024 | Carmen B. Volkart Director | 21,620 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 13, 2024 | Sheri L. Dodd Director | 33,654 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 13, 2024 | Valerie L. Asbury Director | 32,744 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 13, 2024 | D. Brent Shafer Director | 32,744 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 13, 2024 | B. Vindell Washington Director | 19,169 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 13, 2024 | Raymond O. Huggenberger Director | 40,242 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 13, 2024 | William W. Burke Director | 25,273 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $14.06 per share | 355,338.38 |
| May 9, 2024 | Kristie T. Burns Sr. VP Mktg & Clinical Affairs | 62,574 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $14.37 per share | 899,188.38 |
| Mar 1, 2024 | Daniel L. Reuvers President and CEO; Director | 239,423 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $15.6 per share | 3,734,998.80 |
| Mar 1, 2024 | Daniel L. Reuvers President and CEO; Director | 238,027 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $15.25 per share | 3,629,911.75 |
| Mar 1, 2024 | Kristie T. Burns Sr. VP Mktg & Clinical Affairs | 63,389 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $15.25 per share | 966,682.25 |
| Feb 28, 2024 | Daniel L. Reuvers President and CEO; Director | 250,351 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 28, 2024 | Daniel L. Reuvers President and CEO; Director | 244,112 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $15.81 per share | 3,859,410.72 |
| Feb 28, 2024 | Kristie T. Burns Sr. VP Mktg & Clinical Affairs | 65,527 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 28, 2024 | Kristie T. Burns Sr. VP Mktg & Clinical Affairs | 63,512 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $15.9 per share | 1,009,840.80 |